Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 6/20 | 0.66 |
| ▸ | HSD17B2 | P37059 | 6/20 | 0.66 |
| ▸ | BCL2 | P10415 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | BAD | Q92934 | 1/20 | 0.56 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.55 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24751 | 0.88 | HSD17B1 (0.62) | HSD17B1HSD17B2BCL2MCL1BAD | |
| Bromide SCHEMBL28862925 | 0.87 | HSD17B1 (0.61) | HSD17B1HSD17B2BCL2MCL1BAD | |
| SCHEMBL4088536 | 0.86 | HSD17B1 (0.68) | HSD17B1HSD17B2BCL2MCL1BAD | |
| SCHEMBL14020417 | 0.86 | HSD17B1 (0.64) | HSD17B1HSD17B2BCL2MCL1BAD | |
| SCHEMBL11989060 | 0.86 | HSD17B1 (0.60) | HSD17B1HSD17B2BCL2MCL1BAD | |
| SCHEMBL28901460 | 0.86 | HSD17B1 (0.60) | HSD17B1HSD17B2BCL2MCL1BAD | |
| SCHEMBL6319718 | 0.84 | ALDH1A1 (0.66) | HSD17B1HSD17B2MCL1ALDH1A1NPC1 | |
| SCHEMBL30049 | 0.84 | HSD17B1 (0.76) | HSD17B1HSD17B2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14020155 | 0.84 | PDE10A (0.58) | HSD17B1HSD17B2BCL2MCL1BAD | |
| SCHEMBL31407 | 0.83 | HSD17B1 (0.79) | HSD17B1HSD17B2BCL2MCL1BAD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1063443-C | Novel benzothiazole derivatives | NIPPON INTERNAL ORGANS PHARMAC (JP) | 2001-03-21 | — | — | CN | claimed |
| US-5900426-A | ANTILIPEMIC AGENTS | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1999-05-04 | — | — | US | claimed |
| EP-0735029-B1 | Benzothiazole derivatives | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1998-06-03 | — | — | EP | claimed |
| CN-1137524-A | Novel benzothiazole derivatives | NIPPON INTERNAL ORGANS PHARMAC (JP) | 1996-12-11 | — | — | CN | claimed |
| EP-0735029-A1 | Benzothiazole derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1996-10-02 | — | — | EP | claimed |
| US-8329700-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329700-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329700-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120277209-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277209-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277209-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2364308-B1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2010057121-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010057121-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| CN-1063443-C | Novel benzothiazole derivatives | NIPPON INTERNAL ORGANS PHARMAC (JP) | 2001-03-21 | — | — | CN | disclosed |
| US-5900426-A | ANTILIPEMIC AGENTS | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1999-05-04 | — | — | US | disclosed |
| EP-0735029-B1 | Benzothiazole derivatives | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1998-06-03 | — | — | EP | disclosed |
| CN-1137524-A | Novel benzothiazole derivatives | NIPPON INTERNAL ORGANS PHARMAC (JP) | 1996-12-11 | — | — | CN | disclosed |
| EP-0735029-A1 | Benzothiazole derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1996-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | HSD17B1 112/4885HSD17B2 181/4885BCL2 2049/4885 |
| US-20120277209-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | HSD17B1 229/4885HSD17B2 366/4885BCL2 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.